CN104502554A - 一种他达那非及其类似物的纳米胶体金标记免疫测定方法 - Google Patents
一种他达那非及其类似物的纳米胶体金标记免疫测定方法 Download PDFInfo
- Publication number
- CN104502554A CN104502554A CN201410777149.0A CN201410777149A CN104502554A CN 104502554 A CN104502554 A CN 104502554A CN 201410777149 A CN201410777149 A CN 201410777149A CN 104502554 A CN104502554 A CN 104502554A
- Authority
- CN
- China
- Prior art keywords
- tadalafil
- analog
- antibody
- detection
- line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000835 tadalafil Drugs 0.000 title claims abstract description 128
- 238000003018 immunoassay Methods 0.000 title claims abstract description 16
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 title claims abstract 41
- 239000003550 marker Substances 0.000 title abstract 2
- 238000001514 detection method Methods 0.000 claims abstract description 58
- 239000000427 antigen Substances 0.000 claims abstract description 48
- 102000036639 antigens Human genes 0.000 claims abstract description 48
- 108091007433 antigens Proteins 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 40
- 230000036039 immunity Effects 0.000 claims abstract description 16
- 150000002148 esters Chemical class 0.000 claims abstract description 13
- 230000003053 immunization Effects 0.000 claims abstract description 13
- 230000008878 coupling Effects 0.000 claims abstract description 9
- 238000010168 coupling process Methods 0.000 claims abstract description 9
- 238000005859 coupling reaction Methods 0.000 claims abstract description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims abstract description 7
- 229940098773 bovine serum albumin Drugs 0.000 claims abstract description 7
- 241001465754 Metazoa Species 0.000 claims abstract description 6
- 238000002372 labelling Methods 0.000 claims abstract 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000000084 colloidal system Substances 0.000 claims description 16
- 239000010931 gold Substances 0.000 claims description 16
- 229910052737 gold Inorganic materials 0.000 claims description 16
- 238000007689 inspection Methods 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 150000001718 carbodiimides Chemical class 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 241000283707 Capra Species 0.000 claims description 8
- 239000003365 glass fiber Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000000020 Nitrocellulose Substances 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 7
- 229920001220 nitrocellulos Polymers 0.000 claims description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- 238000010189 synthetic method Methods 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 5
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 238000001212 derivatisation Methods 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 230000009514 concussion Effects 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 230000003381 solubilizing effect Effects 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- 241000416536 Euproctis pseudoconspersa Species 0.000 claims description 2
- 238000012764 semi-quantitative analysis Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 39
- 229940079593 drug Drugs 0.000 abstract description 18
- 230000036541 health Effects 0.000 abstract description 3
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- 108010058846 Ovalbumin Proteins 0.000 abstract 1
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 79
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 15
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 15
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 10
- 230000001276 controlling effect Effects 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 235000013305 food Nutrition 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001875 compounds Chemical group 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000413 hydrolysate Substances 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000151 polyglycol Polymers 0.000 description 3
- 239000010695 polyglycol Substances 0.000 description 3
- 229940094720 viagra Drugs 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- -1 Pfizer) Chemical compound 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940117229 cialis Drugs 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940097443 levitra Drugs 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 108010077055 methylated bovine serum albumin Proteins 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229960002639 sildenafil citrate Drugs 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229960002381 vardenafil Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- VUKJGAVIWMPOOJ-FOIQADDNSA-N aminotadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)N)=C1 VUKJGAVIWMPOOJ-FOIQADDNSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006146 oximation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410777149.0A CN104502554B (zh) | 2014-12-17 | 2014-12-17 | 一种他达那非及其类似物的纳米胶体金标记免疫测定方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410777149.0A CN104502554B (zh) | 2014-12-17 | 2014-12-17 | 一种他达那非及其类似物的纳米胶体金标记免疫测定方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104502554A true CN104502554A (zh) | 2015-04-08 |
CN104502554B CN104502554B (zh) | 2017-11-07 |
Family
ID=52943968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410777149.0A Active CN104502554B (zh) | 2014-12-17 | 2014-12-17 | 一种他达那非及其类似物的纳米胶体金标记免疫测定方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104502554B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105353095A (zh) * | 2015-11-16 | 2016-02-24 | 华南农业大学 | 一种西地那非及其结构类似物的免疫检测方法 |
CN105481859A (zh) * | 2015-11-16 | 2016-04-13 | 华南农业大学 | 一种他达那非及其结构类似物的人工抗原、抗体及其酶联免疫检测试剂盒 |
CN106905318A (zh) * | 2017-02-22 | 2017-06-30 | 广东工业大学 | 氨基他达那非半抗原、人工抗原及其制备方法 |
CN108709990A (zh) * | 2018-03-28 | 2018-10-26 | 韶关学院 | 三元体系免疫竞争法检测拉非类药品的量子点免疫层析检测卡及检测方法 |
CN110133259A (zh) * | 2019-04-28 | 2019-08-16 | 华南农业大学 | 一种他达那非及其类似物的胶体金微孔法检测试剂盒及其制备方法和应用 |
CN111562384A (zh) * | 2020-04-20 | 2020-08-21 | 韶关学院 | 双功能抗原引导的西地那非和他达拉非的抗体阵列检测卡 |
CN114460205A (zh) * | 2022-02-17 | 2022-05-10 | 南京嘉晨医药科技有限公司 | 一种用于检测盐酸伐地那非口崩片溶出曲线的方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101021483A (zh) * | 2007-03-22 | 2007-08-22 | 北京市药品检验所 | 检测他达拉非及其衍生物的一种方法 |
CN101980021A (zh) * | 2010-10-22 | 2011-02-23 | 南通市伊士生物技术有限责任公司 | 一种快速检测***及其衍生物的胶体金层析试纸条及制备方法 |
CN102161662A (zh) * | 2010-08-09 | 2011-08-24 | 江苏省南通药品检验所 | 西地那非及其衍生物的人工合成抗原及其制备方法和应用 |
CN102174474A (zh) * | 2011-01-11 | 2011-09-07 | 南通市伊士生物技术有限责任公司 | 西地那非单克隆抗体及用于检测西地那非的胶体金层析试纸条 |
CN102336831A (zh) * | 2010-07-27 | 2012-02-01 | 天津科技大学 | 一种抗西地那非的特异性抗体 |
CN103267842A (zh) * | 2013-05-15 | 2013-08-28 | 郭杰标 | 检测中成药违法添加双氯芬酸的免疫胶体金方法 |
KR101421100B1 (ko) * | 2013-10-08 | 2014-07-22 | 대한민국 | 고온 기체상 크로마토그래프 분석법을 이용한 발기유발제의 고감도 신속 검출법 |
-
2014
- 2014-12-17 CN CN201410777149.0A patent/CN104502554B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101021483A (zh) * | 2007-03-22 | 2007-08-22 | 北京市药品检验所 | 检测他达拉非及其衍生物的一种方法 |
CN102336831A (zh) * | 2010-07-27 | 2012-02-01 | 天津科技大学 | 一种抗西地那非的特异性抗体 |
CN102161662A (zh) * | 2010-08-09 | 2011-08-24 | 江苏省南通药品检验所 | 西地那非及其衍生物的人工合成抗原及其制备方法和应用 |
CN101980021A (zh) * | 2010-10-22 | 2011-02-23 | 南通市伊士生物技术有限责任公司 | 一种快速检测***及其衍生物的胶体金层析试纸条及制备方法 |
CN102174474A (zh) * | 2011-01-11 | 2011-09-07 | 南通市伊士生物技术有限责任公司 | 西地那非单克隆抗体及用于检测西地那非的胶体金层析试纸条 |
CN103267842A (zh) * | 2013-05-15 | 2013-08-28 | 郭杰标 | 检测中成药违法添加双氯芬酸的免疫胶体金方法 |
KR101421100B1 (ko) * | 2013-10-08 | 2014-07-22 | 대한민국 | 고온 기체상 크로마토그래프 분석법을 이용한 발기유발제의 고감도 신속 검출법 |
Non-Patent Citations (2)
Title |
---|
郭杰标等: "同时检测伐地那非及其类似物的免疫学方法", 《食品与生物技术学报》 * |
高青等: "中药及保健食品中PDE5抑制剂检测方法研究及未知衍生物的发现", 《中国药学杂志》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105353095A (zh) * | 2015-11-16 | 2016-02-24 | 华南农业大学 | 一种西地那非及其结构类似物的免疫检测方法 |
CN105481859A (zh) * | 2015-11-16 | 2016-04-13 | 华南农业大学 | 一种他达那非及其结构类似物的人工抗原、抗体及其酶联免疫检测试剂盒 |
CN105481859B (zh) * | 2015-11-16 | 2017-10-20 | 华南农业大学 | 一种他达那非及其结构类似物的人工抗原、抗体及其酶联免疫检测试剂盒 |
CN105353095B (zh) * | 2015-11-16 | 2017-10-20 | 华南农业大学 | 一种西地那非及其结构类似物的免疫检测方法 |
CN106905318A (zh) * | 2017-02-22 | 2017-06-30 | 广东工业大学 | 氨基他达那非半抗原、人工抗原及其制备方法 |
CN108709990A (zh) * | 2018-03-28 | 2018-10-26 | 韶关学院 | 三元体系免疫竞争法检测拉非类药品的量子点免疫层析检测卡及检测方法 |
CN110133259A (zh) * | 2019-04-28 | 2019-08-16 | 华南农业大学 | 一种他达那非及其类似物的胶体金微孔法检测试剂盒及其制备方法和应用 |
CN111562384A (zh) * | 2020-04-20 | 2020-08-21 | 韶关学院 | 双功能抗原引导的西地那非和他达拉非的抗体阵列检测卡 |
CN114460205A (zh) * | 2022-02-17 | 2022-05-10 | 南京嘉晨医药科技有限公司 | 一种用于检测盐酸伐地那非口崩片溶出曲线的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104502554B (zh) | 2017-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104502554A (zh) | 一种他达那非及其类似物的纳米胶体金标记免疫测定方法 | |
CN102253222B (zh) | 检测***的方法及其专用试纸 | |
CN102621326B (zh) | 一种检测食品中呋喃它酮代谢物含量的方法 | |
Guo et al. | Development of an immunoassay for rapid screening of vardenafil and its potential analogues in herbal products based on a group specific monoclonal antibody | |
CN102827076B (zh) | 一种氟喹诺酮类药物通用半抗原、人工抗原、广谱单克隆抗体及其制备方法与应用 | |
WO2022077824A1 (zh) | 一种匹可硫酸钠半抗原、人工抗原、抗体及其制备方法和应用 | |
CN101443823B (zh) | 黄尿酸衍生物药物组合物及其相关方法 | |
CN108776219A (zh) | 一种快速检测细交链格孢酮酸的免疫层析试纸条 | |
Wang et al. | Indirect competitive enzyme-linked immunosorbent assay based on a broad-spectrum monoclonal antibody for tropane alkaloids detection in pig urine, pork and cereal flours | |
US9435817B2 (en) | Detection of synthetic cannabinoids | |
WO2010101777A1 (en) | Detection of melamine | |
Guo et al. | Development and evaluation of an immunochromatographic strip for rapid screening of sildenafil-type compounds as illegal additives in functional foods | |
CN113248398A (zh) | 一种检测非那西丁的半抗原、人工抗原、抗体及其制备方法和应用 | |
Liu et al. | Development of a GNP-based lateral flow immunoassay for the detection of isoprothiolane in rice samples | |
CN109239336A (zh) | 一种检测异丙威的试纸条及其应用 | |
Zhou et al. | Rapid, on-site quantitative determination of higenamine in functional food using a time-resolved fluorescence microsphere test strip | |
CN106565737A (zh) | 一种黄曲霉毒素b1半抗原、人工抗原及其卵黄抗体的制备方法 | |
CN102353767B (zh) | 一种全成分群同时测算方法 | |
CN103267842B (zh) | 检测中成药违法添加双氯芬酸的免疫胶体金方法 | |
CN101424688A (zh) | 用胶体金免疫层析试验检测氯丙嗪的方法 | |
CN106496323B (zh) | 一种簇选择性赭曲霉毒素人工抗原及其广谱性多克隆抗体的制备方法 | |
Pan et al. | An ic-ELISA and immunochromatographic strip assay for the detection of 2, 4-dichlorophenoxyacetic acid in bean sprouts and cabbage | |
CN101839907A (zh) | 一种苏丹红ⅰ的酶联免疫吸附分析方法 | |
CN112250641A (zh) | 双氢克尿噻半抗原、人工抗原、抗体及其制备方法和应用 | |
CN103364546A (zh) | 一种检测呋喃唑酮代谢物的试剂盒及方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Guo Jiebiao Document name: Notification that Application Deemed to be Withdrawn |
|
DD01 | Delivery of document by public notice |
Addressee: Guo Jiebiao Document name: Notification of Decision on Request for Restoration of Right |
|
DD01 | Delivery of document by public notice | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Guo Jiebiao Inventor after: Zhang Minying Inventor before: Guo Jiebiao |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20170417 Address after: 512005 Guangdong province Shaoguan Zhenjiang University Road No. 288 Applicant after: Shaoguan College Address before: 512005 Guangdong province Shaoguan Zhenjiang University Road No. 2 Applicant before: Guo Jiebiao |
|
TA01 | Transfer of patent application right | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Guo Jiebiao Document name: Notification of Passing Examination on Formalities |
|
GR01 | Patent grant | ||
GR01 | Patent grant |